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Abstract
Background: Toll-like receptor 4 (TLR4) plays a pivotal role in the pathophysiology of stroke-induced inflammation.
Both astroglia and microglia express TLR4, and endogenous ligands produced in the ischemic brain induce
inflammatory responses. Reactive oxygen species (ROS), nitric oxide (NO), and inflammatory cytokines produced by
TLR4 activation play harmful roles in neuronal damage after stroke. Although astroglia exhibit pro-inflammatory
responses upon TLR4 stimulation by lipopolysaccharide (LPS), they may also play cytoprotective roles via the
activation of the pentose phosphate pathway (PPP), reducing oxidative stress by glutathione peroxidase. We
investigated the mechanisms by which astroglia reduce oxidative stress via the activation of PPP, using TLR4
stimulation and hypoxia in concert with microglia.
Methods: In vitro experiments were performed using cells prepared from Sprague–Dawley rats. Coexisting microglia
in the astroglial culture were chemically eliminated using L-leucine methyl ester (LME). Cells were exposed to LPS
(0.01 μg/mL) or hypoxia (1 % O2) for 12–15 h. PPP activity was measured using [1-14C]glucose and [6-14C]glucose.
ROS and NO production were measured using 2′,7′-dichlorodihydrofluorescein diacetate and diaminofluorescein-FM
diacetate, respectively. The involvement of nuclear factor-erythroid-2-related factor 2 (Nrf2), a cardinal transcriptional
factor under stress conditions that regulates glucose 6-phosphate dehydrogenase, the rate-limiting enzyme of PPP,
was evaluated using immunohistochemistry.
Results: Cultured astroglia exposed to LPS elicited 20 % increases in PPP flux, and these actions of astroglia
appeared to involve Nrf2. However, the chemical depletion of coexisting microglia eliminated both increases in PPP
and astroglial nuclear translocation of Nrf2. LPS induced ROS and NO production in the astroglial culture containing
microglia but not in the microglia-depleted astroglial culture. LPS enhanced astroglial ROS production after glutathione
depletion. U0126, an upstream inhibitor of mitogen-activated protein kinase, eliminated LPS-induced NO production,
whereas ROS production was unaffected. U0126 also eliminated LPS-induced PPP activation in astroglial–microglial
culture, indicating that microglia-derived NO mediated astroglial PPP activation. Hypoxia induced astroglial PPP
activation independent of the microglia–NO pathway. Elimination of ROS and NO production by sulforaphane, a
natural Nrf2 activator, confirmed the astroglial protective mechanism.
Conclusions: Astroglia in concert with microglia may play a cytoprotective role for countering oxidative stress in stroke.
Keywords: Ara-C (cytosine β-D-arabinofuranoside hydrochloride), Astrocyte, LME (L-leucine methyl ester), RNS
(reactive nitrogen species), ROS (reactive oxygen species), TLR4 (Toll-like receptor 4)
* Correspondence: takashin@tka.att.ne.jp
1Department of Neurology, Keio University School of Medicine, 35
Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan
Full list of author information is available at the end of the article
© 2016 Iizumi et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Iizumi et al. Journal of Neuroinflammation  (2016) 13:99 
DOI 10.1186/s12974-016-0564-0
Background
Although multiple mechanisms underlie the pathophysi-
ology of ischemic stroke, there is increasing evidence
that inflammation accounts for its progression [1, 2]. A
robust inflammatory reaction characterized by peripheral
leukocyte influx into the cerebral parenchyma and the
activation of endogenous microglia follows focal cerebral
ischemia [3–7]. Reactive oxygen species (ROS) and
reactive nitrogen species (RNS) play pivotal roles in
neuronal damage. ROS and/or RNS are, at least in part,
produced by cerebral parenchymal cells, including neu-
rons and glial cells, as well as peripheral inflammatory
cells such as leukocytes. The origin of ROS appears to
be from activated NADPH oxidase (NOX), and ROS, in
turn, reacts with nitric oxide (NO) produced by acti-
vated inducible nitric oxide synthase (iNOS), leading to
peroxynitrite generation, which is a highly toxic reactive
species that can induce lipid peroxidation and protein
oxidative damage [8]. Thus, the intrinsic protective
mechanism that eliminates ROS may play an important
role in countering post-stroke inflammation.
Toll-like receptors (TLRs) mediate innate immune
response, and recent findings suggest that they also me-
diate post-stroke inflammatory responses [9]. There are
at least 11 TLR proteins in mammals [10], and TLR4 is
implicated in the pathogenesis of stroke-related inflam-
mation. TLR4 is predominantly expressed in both micro-
glia and astroglia, and also in neurons [11]. Although
lipopolysaccharide (LPS), a component of bacterial cell
walls, is a well-known classical ligand of TLR4, extracel-
lular matrix and dysfunctional mitochondria released
from damaged cells have been reported to be endogen-
ous ligands of TLR4 [12]. TLR4 stimulation of microglia
plays a harmful role in stroke through downstream sig-
naling pathways: myeloid differentiation protein 88–nu-
clear factor κB (NFκB), mitogen-activated protein kinase
(MAPK), also called extracellular signal-regulated kinase
1/2, and Janus kinases, which are signal transducers and
activators of transcription. In particular, the activation of
NFκB induces NOX and iNOS, which enhance ROS and
NO production by microglia.
Astroglia express TLR4 even in the human brain, and
the stimulation of TLR4 by LPS in cultured astroglia in-
duces pro-inflammatory responses [13]. In contrast, LPS
may also induce an astroglial anti-inflammatory, protect-
ive function via the pentose phosphate pathway (PPP)
[14]. PPP is a shunt pathway of glycolysis and produces
NADPH, which recycles the oxidized from of glutathi-
one (GSH) back to the reduced form, leading to the
removal of ROS by GSH peroxidase. Thus, PPP activity
is an index of endogenous neuroprotective function. In
fact, astroglial PPP activity is much higher than that of
neurons [15], and PPP activation plays an important role
in countering oxygen stress. The activation of astroglial
TLR4 by LPS activates astroglial PPP through NO
[14, 16, 17]. The exact mechanism by which NO acti-
vates PPP remains to be elucidated.
The rate-limiting enzyme of PPP, glucose 6-phosphate
dehydrogenase (G6PDH), is regulated both allosterically
and transcriptionally. Under stress conditions, the
master regulator of the anti-stress response, the Kelch-
like ECH-associated protein 1 (Keap1)/nuclear factor-
erythroid-2-related factor 2 (Nrf2) system induces vari-
ous enzymes via transcriptional regulation mediated by
Nrf2. In fact, G6PDH also harbors an antioxidant re-
sponse element (ARE) to which Nrf2 binds and initiates
the transcription of G6PDH, leading to PPP activation
[18]. Nrf2 is bound to its adaptor protein Keap1 and is
constantly degraded by the ubiquitin–proteasome sys-
tem in the cytosol. However, several signals can affect
the cysteine residues of Keap1 to induce a conform-
ational change for releasing Nrf2. Free Nrf2 translocates
into the nucleus and initiates transcription. Numerous
reports show that both ROS and/or NO can induce Keap1
conformational change and Nrf2 activation [19–22]. Thus,
TLR4-mediated production of ROS, NO, or both by astro-
glia is a potential mediator.
Another important issue that should be clarified is the
cellular origin of ROS or NO. There is no doubt that
LPS induces ROS and NO production in microglia.
However, whether astroglial ROS and NO production
are induced by LPS remains to be established. Most
studies describing the astroglial response to LPS have
been based on cell culture experiments [23]. Usually, an
astroglial culture contains a small (<10 %) population of
microglia. If LPS acts on microglia, even on <10 % of
the total cells, microglia can produce sufficient ROS and
NO in response to LPS.
The present study used a conventional secondary
astroglial culture prepared from pups of Sprague–Dawley
rats. To eliminate microglial cells, the conventional
astroglial culture was treated with cytosine β-D-arabino-
furanoside hydrochloride (Ara-C), followed by L-leucine
methyl ester (LME) [24, 25]. This procedure completely
eliminates Iba1-positive cells. We used both microglia-
present and microglia-absent astroglial cultures and eval-
uated PPP activity, as well as ROS and NO production
in response to LPS.
Methods
Animals
Timed-pregnant Sprague–Dawley rats were obtained
from Japan SLC, Inc. (Hamamatsu, Japan). Male C57BL/
6 (wild-type (WT)) mice (Japan SLC, Inc.) and Nrf2
gene knockout (KO) mice (on C57BL/6 background, ori-
ginally generated by Dr. Masayuki Yamamoto) were used
in this study. Nrf2-KO mice were genotyped by PCR
amplification of genomic DNA extracted from tail snips.
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All animal procedures were performed in accordance
with The Animal Experimentation Guidelines of Keio
University School of Medicine and were approved by the
Committee on Animal Care and Use, Keio University
(08097-[15]).
Chemicals
Chemicals and materials were obtained from the follow-
ing sources: Insta-Fluor Plus and Hyamine hydroxide 10-
X from Perkin-Elmer Life Sciences (Boston, MA, USA);
D-[1-14C]glucose (specific activity, 2.035 GBq/mmol) and
D-[6-14C]glucose (specific activity, 2.035 GBq/mmol)
from American Radiolabeled Chemicals, Inc. (St. Louis,
MO, USA); normal goat serum from Jackson ImmunoRe-
search (West Grove, PA, USA); rabbit Iba1 antibody from
Wako Pure Chemical Industries (Osaka, Japan); mouse
monoclonal anti-glial fibrillary acidic protein (GFAP)
from Sigma (St. Louis, MO, USA); goat polyclonal
antibody against TLR4 from Santa Cruz Biochemistry
(Delaware, CA, USA); 1,4-diamino-2,3-dicyano-1,4-
bis[2-aminophenylthio] butadiene (U0126), a selective
inhibitor of MAPK/ERK kinase1/2 (MEK1/2) from Cell
Signaling Technology (Danvers, MA, USA); mouse
monoclonal antibody against anti-β actin from Abcam
(Cambridge, UK); rabbit anti-Nrf2 (H-300) polyclonal
antibody, rhodamine-conjugated goat anti-mouse (for
GFAP), anti-rabbit (for Nrf2) IgG antibody, and
fluorescein-isothiocyanate (FITC)-conjugated goat anti-
rabbit (for Iba1) antibody from Santa Cruz Biochemis-
try; Dulbecco’s modified Eagle media (DMEM) with or
without glucose, penicillin, and streptomycin from Life
Technologies (Grand Island, NY, USA); defined fetal
bovine from HyClone Laboratories (Logan, UT, USA);
2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA)
and monochlorobimane (MCB) from Molecular Probe
Inc. (Eugene, OR, USA); diaminofluorescein-FM diace-
tate (DAF-FM DA) from Sekisui Medical (Chuo-ku,
Tokyo, Japan); and all other chemicals were obtained
from Sigma (St. Louis, MO, USA).
Preparation of cells
Primary astroglial cultures were prepared from the rat
or mouse cerebral cortices 24–48 h after birth [26].
Dissociated cells from the cerebral cortices (2.5 × 105
cells/mL for rat and 5.0 × 105 cells/mL for mouse)
were plated (15 mL/flask) in uncoated 75-cm2 culture
flasks (Sumitomo Bakelite, Tokyo, Japan) and cultured
in a glucose-containing medium (final concentration,
12 mmol/L of D-glucose) comprising DMEM with
10 % (v/v) fetal bovine serum, penicillin (100 U/mL),
and streptomycin (100 μg/mL) at 37 °C in humidified
air containing 21 % O2 and 7 % CO2 (day 0). The
culture medium was changed every 2 days until the
cultures reached confluence. On day 11, the adherent
cells were treated with trypsin–EDTA solution, sus-
pended in a fresh high (12 mmol/L)-glucose medium,
and placed in uncoated 12-well culture plates (0.8 mL/
well, respectively; Nalge Nunc, Rochester, NY, USA) or
in 25-cm2 culture flasks (5 mL/flask; Nalge Nunc).
For immunohistochemical staining, the cells were
plated (2 mL/dish) on 35-mm glass-bottomed dishes
(Matsunami Glass, Industry, Osaka, Japan) precoated
with poly-L-lysine. Some cells were grown on glass-
bottomed 24-well culture plates (EZView culture plate
LB, Iwaki, Tokyo, Japan) for fluorometric assay. From
the day after subculturing, the cells were cultured in
DMEM, fetal bovine serum, penicillin, and strep-
tomycin and a final D-glucose concentration of
12 mmol/L for 10 days. The culture medium was
changed twice a week, and the cells were used once
they reached confluence (on day 21 in vitro). Some
secondary astroglial cells were treated with Ara-C
followed by LME to eliminate microglia.
Primary neuronal cultures were prepared from the
striatum of fetal rats on embryonic day 16, as previously
described [26]. Mechanically dissociated cells were
placed in 12-well culture plates (0.8 mL/well, respect-
ively) or 25-cm2 culture flasks (5 mL/flask) coated with
poly-L-lysine (5 μg/mL). For the neuronal cultures,
viable cells (1.5 × 106 cells/mL) that excluded trypan blue
were placed in the cultures, and Ara-C (10 μmol/L) was
added 72 h later to induce mitotic arrest of the astroglia.
The cells were cultured in a glucose medium (final con-
centration, 12 mmol/L D-glucose) at 37 °C in humidified
air containing 21 % O2 and 7 % CO2. In vitro assays
were performed using cultures that were 7 or 8 days old.
The nutrient medium remained untouched until the
experiments were initiated.
Microglial cells were obtained by collecting floating or
loosely adherent cells in primary astroglial culture and
were placed in 12-well culture plates or glass-bottomed
dishes precoated with poly-L-lysine [27].
Depletion of microglia from astroglial cultures
Usually, secondary astroglial cultures contain only small
amounts (<10 % of total cells) of microglia, as previously
described [27, 28]. To eliminate all possible metabolic
effects of microglial contamination, the treatment with a
combination of Ara-C and LME was applied according
to the method described by Pont-Lezica et al. [25].
Briefly, 10 μmol/L (final concentration in nutrient
medium) of Ara-C was added to the astroglial culture
3 days prior to the assay. After 48 h, cells were further
incubated with 50 mmol/L of LME (pH adjusted to ~7.4)
for 60 min. Cells were then washed with phosphate-
buffered saline (PBS) without Ca2+ and Mg2+ and further
cultured with a regular nutrient medium for 24 h. This
treatment destroyed microglia by osmotic effects and
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yielded almost 100 % pure astroglial cell culture. The
exact mechanism by which LME eliminates microglia
remains to be elucidated. It has been speculated that
LME is internalized by microglia, wherein it causes lyso-
somal disruption and subsequent apoptosis. In fact, mac-
rophages and microglia are characteristically rich in
lysosomes, causing them to be particularly vulnerable
upon exposure to LME treatment [29, 30].
Experimental protocol
To assess the effects of LPS on astroglial PPP activation,
ROS/NO production, and immunohistochemistry, the
nutrient medium (12 mmol/L) was removed and fresh
nutrient medium containing LPS (0.01, 0.1, or 1 μg/mL)
was added and kept in a CO2 incubator for 15 h. For
neuronal cultures, a medium change per se damages cells
via glutamate toxicity [31], LPS was directly added to the
culture media of cells to obtain final concentrations of
0.01, 0.1, or 1 μg/mL, as described above. When astro-
glial cells were exposed to 1-isothiocyanato-(4R,S)-
(methylsulfinyl)butane (sulforaphane), an Nrf2 activator
[32–34] or S-nitroso-N-acetyl-DL-penicillamine (SNAP),
an NO donor [35], the nutrient medium was replaced
with a fresh medium containing the drug or vehicle (di-
methyl sulfoxide (DMSO)), and cells were incubated for
15 h. When the effects of sulforaphane (10 μmol/L),
U0126 (10 μmol/L), L-buthionine-sulfoximine (BSO;
50 μmol/L)—an inhibitor of GSH synthesis [36]—on
LPS-induced ROS/NO production were assessed, cells
were pre-incubated with these drugs for 12 h before LPS
treatment and further incubated for 12 h with LPS,
followed by the measurement of ROS and NO.
We next assessed the effects of hypoxia because it is
also well recognized that hypoxic conditions per se
shift the cellular metabolism from oxidative to glyco-
lytic in various cells. However, whether hypoxia
A B
C D
Fig. 1 Chemical depletion of microglia by Ara-C/LME. Ara-C/LME treatment removed Iba1-positive cells. Representative photographs showing
fluorescent immunostaining of DAPI (blue), Iba1 (green), or GFAP (red) in the secondary astroglial culture. In untreated astroglia, there was a small
number of Iba1-positive cells. Scale bar, 50 μm (a). After Ara-C/LME-treatment, Iba1-positive cells disappeared. Scale bar, 50 μm (b). In untreated
astroglia, 10.8 ± 0.16 (%) of Iba 1-positive cells were observed, while in Ara-C/LME-treated astroglia, only 0.5 ± 1.0 (%) of cells were Iba1-positive.
Values are the means ± SD of four areas (c). Western blotting showed that both the normal astroglial culture (with microglia) and Ara-C/LME-
treated astroglial culture (without microglia) expressed TLR4 (d)
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enhances PPP flux has not been addressed. An early
study revealed that chronic hypoxia induced PPP
activity in C6 glioma cells [37], but the mechanism
that conveys the hypoxic signal for PPP activation is
undetermined. In a recent study [38], hypoxia and re-
perfusion induced PPP activation in astroglia. Al-
though the underlying mechanism was not described,
the reperfusion-induced massive production of ROS in
association with NO might exert a strong influence on
PPP activation. Moreover, the effect of LPS or LPS in
combination with hypoxia on astroglial PPP activity
has not been reported. In the present study, we exam-
ined the effect of LPS stimulation in combination with
hypoxia on PPP flux in astroglia. To assess the effect
of hypoxia on PPP activation, we placed cells for 12
or 24 h in a hypoxic chamber (multi-gas incubator
APM-30DR, ASTEC, Fukuoka-ken, Japan) at 37 °C in
humidified air containing 1 % O2 and 7 % CO2. We
assessed the combined effects of LPS (0.01 μg/mL)
and hypoxia (1 % O2) for 15 h in some neuronal and
astroglial cells.
Measurement of the rates of D-[1-14C]glucose and
D-[6-14C]glucose oxidation to 14CO2
The rate of [14C]glucose oxidation to 14CO2 was mea-
sured using a modification of a previously described
method [39] after cells cultured in 25-cm2 culture flasks
were washed twice with PBS containing no glucose. The
assay solutions consisted of Dulbecco’s balanced salt so-
lution (DBSS) containing (mmol/L) 110 NaCl, 5.4 KCl,
1.8 CaCl2, 0.8 MgSO4, 0.9 NaH2PO4, and 44 NaHCO3,
in addition to 2 mmol/L of D-glucose labeled with
1.0 μL/mL of D-[1-14C]glucose or D-[6-14C]glucose
(original concentrations, 3.7 MBq/mL), were added,
and the flasks were capped with rubber stoppers con-
taining a center well and incubated at 37 °C for 60 min.
The 14CO2 produced was trapped by a cotton ball
placed in the center well containing 100 μL of Hyamine
hydroxide 10-X. The reactions were terminated by the
injection of 250 μL of perchloric acid (2 mol/L) through
the rubber stopper, and the flasks were kept at 4 °C
overnight to trap the 14CO2. The center wells were then
transferred to 20-mL glass scintillation counter vials,
A B
C D
Fig. 2 Microglia-enriched culture produced both ROS and NO in response to LPS. Representative photographs showing only Iba1-positive (green)
cells in the microglial culture. Scale bar, 50 μm (a). After Ara-C/LME-treatment, Iba1-positive cells disappeared. Scale bar, 50 μm (b). LPS induced
both ROS (c ROS) and NO (d NO) production. The rate of ROS/NO production was expressed as percent increase in the fluorescent signal at
60 min compared with that at 0 min. Values are the means ± SD of four wells. ***P < 0.001 versus control (grouped t test)




Fig. 3 (See legend on next page.)
Iizumi et al. Journal of Neuroinflammation  (2016) 13:99 Page 6 of 20
and 500 μL of ethanol and 10 mL of Insta-Fluor Plus
were added. The 14C contents of the vials were evaluated
in a liquid scintillation counter. The assay solutions con-
sisted of 2.5 mL of DBSS containing 2 mmol/L D-glucose;
these solutions were labeled by the addition of 1.0 μL/mL
of D-[1-14C]glucose or D-[6-14C]glucose (original concen-
trations, 3.7 MBq/mL).
Waniewski and Martin [40] reported that substan-
tial 14C counts were obtained from a flask without
cells. Accordingly, the 14C counts obtained from a flask
without cells in which the reaction had been stopped at
60 min were treated as background values and were sub-
tracted from the measured counts. The cell carpets
remaining in the incubation flasks after the removal of
the reaction mixtures were then digested with 5 mL of
0.1 M NaOH, and their protein contents were determined
using the bicinchoninic acid (BCA) assay kit (Thermo
Scientific Pierce, Rockford, IL, USA). The rates of total
glucose oxidation (pmol glucose/μg protein/60 min)
based on the conversion from [14C]glucose to 14CO2 over
60 min were measured.
Measurement of PPP activity in cultured astroglia and
neurons
PPP activity was measured using a modification of the
method described by Hothersall et al. [41]. Briefly,
cells were incubated with glucose with tracer doses of
[1-14C]glucose or [6-14C]glucose for 60 min, and the
PPP rate calculated as the difference between the 14CO2
derived from [1-14C]glucose (metabolized by both PPP
and the tricarboxylic acid [TCA] cycle,) and that derived
from [6-14C]glucose (metabolized by only the TCA cycle)
was taken as an indicator of PPP activity.
Measurement of ROS and NO production
The production of ROS, mainly H2O2, and NO in cells
was assessed by H2DCFDA [42] and DAF-FM DA [43]
using semiquantitative fluorometric measurement. Im-
mediately prior to the assay, the nutrient medium was
removed and the cells were washed twice with PBS with-
out glucose. Then, DBSS containing 10 μmol/L of
H2DCFDA or DAF-FM DA dissolved in DMSO (final
volume of DMSO 0.1 %) supplemented with 2 mmol/L
glucose were added, and the cells were incubated at
37 °C in humidified air with 7 % CO2 for 30 min. After
the H2DCFDA or DAF-FM DA were loaded for 30 min,
the cells were washed twice again with PBS without
glucose and DBSS containing 2 mmol/L D-glucose. The
cells were further incubated for 60 min, and the fluor-
escence level indicating intracellular ROS or NO pro-
duction was measured at 0 and 60 min using a
fluorescent microplate reader (Infinite 200 PRO; Tecan
Japan, Kanagawa, Japan) with excitation at 485 nm and
emission at 530 nm. As the fluorescent signals linearly
increased for up to 60 min (data not shown), the results
were expressed as the percent increase in fluorescent
signal at 60 min compared with that at 0 min.
Measurement of total glutathione content using a
fluorometric method
The intracellular content of total glutathione in astroglia
was assessed using MCB which forms an adduct with
glutathione via an enzymatic reaction catalyzed by gluta-
thione transferases [44]. Cells were incubated with MCB
(50 μmol/l) for 30 min. The intracellular formation of
the GSH–MCB adduct was assessed using a microplate
reader with excitation at 360 nm and emission at
465 nm. The results were expressed as the fluorescence
signal standardized by cellular protein content.
Immunohistochemistry
The translocation of Nrf2 from the cytosol to the
nucleus was assessed using immunohistochemistry.
Astroglial cells grown in a glass-bottomed 35-mm dish
were fixed with 4 % paraformaldehyde for 10 min on
ice. The cells were permeabilized with 0.5 % Triton X-
100 for 10 min at room temperature, followed by post-
fixation with 4 % paraformaldehyde for 5 min on ice.
For immunostaining, the cells were washed twice with
PBS containing MgCl2 and CaCl2, and nonspecific IgG
binding sites were blocked by the incubation of cells in
PBS containing 3 % bovine serum albumin and 3 %
normal goat serum for 30 min at room temperature.
Cells were incubated with primary antibodies (anti-
GFAP [1:200], anti-Iba1 [1:200], and anti-Nrf2 poly-
clonal antibody [1:100]) for 2 h at room temperature.
(See figure on previous page.)
Fig. 3 The effects of chemical depletion of microglia. Chemical depletion of microglia eliminated LPS-induced production of ROS and NO and
astroglial PPP activation. The rate of ROS/NO production was expressed as percent increase in the fluorescent signal at 60 min compared with
that at 0 min. The rate of ROS production in the secondary astroglial culture exposed to LPS (0.01 μg/mL) for 12 h (a ROS), and the rate of NO
production in the secondary astroglial culture exposed to LPS (0.01 μg/mL) for 12 h (b NO). Open columns, untreated astroglia. Striped columns,
Ara-C/LME-treated astroglia. Values are the means ± SD of six wells. n.s., not significant, ***P < 0.001 versus control (grouped t test). PPP flux in
untreated astroglia (c PPP) and in microglia-depleted astroglia (d PPP) after 15-h exposure to various concentrations of LPS as indicated in the
figure. PPP flux increased in untreated astroglia at LPS of 0.01 μg/mL, but not in microglia-depleted astroglia. Values are the means ± SD of four
flasks. n.s., not significant, **P < 0.01 versus control (ANOVA followed by Dunnett’s test). Representative photographs showing immunofluorescent
staining with DAPI (blue), GFAP (green), or Nrf2 (red) in the secondary astroglial cultures. LPS (0.01 μg/mL) for 12 h induced the nuclear translocation
of Nrf2 in microglia-containing astroglia (e), but did not in microglia-depleted astroglia (f). Scale bar, 50 μm




Fig. 4 (See legend on next page.)
Iizumi et al. Journal of Neuroinflammation  (2016) 13:99 Page 8 of 20
They were then incubated with the secondary anti-
bodies (rhodamine-conjugated goat anti-rabbit IgG
antibody or FITC-conjugated goat anti-mouse IgG anti-
body) with 4′,6-diamino-2-phenylindole (DAPI) for nu-
clear staining for 1 h. The cells were examined using a
laser confocal microscopy system (Leica TCS SP5; Leica
Microsystems, Exton, PA, USA).
Western blotting
Cells were homogenized in an ice-cold lysis buffer;
radioimmunoprecipitation assay buffer, 0.5 % sodium
dodecyl sulfate, ~0.1 M phenylmethanesulfonyl fluoride,
and protease inhibitor cocktail. The concentration of
total protein in the supernatant was determined using
the BCA protein assay kit (Thermo Scientific Pierce,
Rockford, IL, USA). The proteins were separated using
10 % sodium dodecyl sulfate polyacrylamide gel electro-
phoresis and electrophoretically transferred to polyviny-
lidene difluoride membranes (Millipore Corporation,
Bedford, MA, USA). After treatment for 1 h with a
blocking solution containing 5 % nonfat dry milk, the
membrane was incubated with anti-TLR4 antibody
(1:200), and anti-β actin antibody (1:5000). After wash-
ing, the membranes were reacted with the second bod-
ies, the membrane was incubated with horse-radish
peroxidase-conjugated anti-goat (Santa Cruz), or anti-
mouse antibody (Jackson ImmunoResearch) and the
immunoreactive bands were visualized by enhanced
chemiluminescence and detected with a lumino-image
analyzer (Las-4000; Fujifilm, Tokyo, Japan).
Evaluation of Nrf2 activation by quantitative reverse
transcription PCR (qRT-PCR) analysis for mRNA of heme
oxygenase-1 (HO-1)
Total RNA from cultured cells was isolated using
RNeasy mini kit (Qiagen, Valencia, CA) with a DNase
(Qiagen, Valencia, CA) treatment. First-stranded cDNA
was synthesized using PrimeScript RT reagent Kit
(TaKaRa) according to the manufacturer’s instructions.
qRT-PCR was performed using predesigned gene-spe-
cific TaqMan Gene Expression Assays (Applied Biosys-
tems) with the StepOnePlus real-time PCR system
(Applied Biosystems). Rat HO-1 TaqMan probe and
primers (cat# Rn00561387_m1) and rat GAPDH TaqMan
probe and primers (cat# Rn01775763_g1) were from
Applied Biosystems. The housekeeping gene glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) was used for
normalization. The fold difference between levels of tran-
scripts was calculated using the ΔΔCT method.
Quantification of metabolites by capillary-electrophoresis/
electrospray ionization (CE/ESI) MS
The PPP flux and other metabolic pathway of glucose
were analyzed using CE/ESI MS (Additional file 1).
Statistical analyses
Statistical comparisons among the values obtained for
each group were performed using grouped t tests or
one-way analysis of variance followed by the Dunnett
test for multiple comparisons. A P value of <0.05 was
considered statistically significant.
Results
Ara-C/LME treatment eliminated microglia in the
secondary astroglial culture
As shown in Fig. 1a, b, the secondary astroglial culture
mainly consists of GFAP-positive astrocytes (red). How-
ever, immunostaining with Iba1 (green) showed a small
number of microglia coexisting with the astroglia
(Fig. 1a). After Ara-C/LME-treatment, Iba1-positive cells
were completely removed (Fig. 1b). The Iba1-positive
cells were counted and shown as % of the total number
of cells counted with DAPI (Fig. 1c). The proportion of
microglia in the normal astroglial culture was approxi-
mately 10 %, as previously reported, but was reduced to
zero after treatment with Ara-C/LME. Western blot
analysis (Fig. 1d), however, showed TLR4 expression in
the microglia-depleted astroglial culture as well as
microglia-containing astroglia, indicating that cultured
astroglial cells indeed harbor TLR4 and can potentially
respond to the LPS stimulation.
Microglia-enriched culture produced both ROS and NO in
response to LPS
We cultured primary microglial cells from primary
astroglial cultures. As shown in Fig. 2a, Iba1-positive
cells without GFAP-positive cells were obtained. Ara-C/
LME treatment eliminated almost all Iba1-positive cells,
(See figure on previous page.)
Fig. 4 The effects of U0126-pretreatment on microglia and astroglia. U0126 pretreatment eliminated LPS-induced production of NO in untreated
astroglia and in microglia. The rate of ROS production (a ROS) and the rate of NO production (b NO) in the astroglial culture exposed to LPS
(0.01 μg/mL) for 12 h in the presence or absence of U0126 (10 μmol/L). Cells had been incubated with U0126 for 12 h before exposure to LPS.
Values are the mean ± SD of six wells. n.s., not significant, **P < 0.01, ***P < 0.001 versus control (grouped t test). The rate of ROS production (c ROS),
and the rate of NO production (d NO) in the microglial culture exposed to LPS (0.01 μg/mL) for 12 h in the presence or absence of U0126 (10 μmol/L).
Basal production of ROS and NO in astroglia or microglia was assessed with or without pretreatment of U0126 for 24 h. ROS production was reduced
by U0126 in microglia, while astroglial ROS production was not affected (e ROS). Neither astroglial nor microglial NO production was altered by U0126
pretreatment (f NO). Values are the mean ± SD of four wells. n.s., not significant, *P < 0.05, **P < 0.01 versus control (grouped t test)
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as expected (Fig. 2b). LPS (0.01 μg/mL for 12 h) induced
both ROS and NO production in these Iba1-positive
cells (Fig. 2c, d).
LPS-induced production of ROS and NO disappeared after
chemical depletion of microglia
Astroglial cells containing microglia showed marked ele-
vation in the rates of ROS (Fig. 3a) and NO (Fig. 3b)
production after exposure to LPS (0.01 μg/mL) for 12 h.
However, these increases were eliminated after micro-
glial depletion (Fig. 3a, b).
LPS induced increases in PPP flux in microglia-containing
astroglia, but not in microglia-depleted astroglia
As shown in Fig. 3c, the effect of LPS on increasing PPP
flux in astroglia was evident only in the presence of
microglia. LPS did not induce PPP activation after the
elimination of microglia (Fig. 3d).
LPS induced nuclear translocation of Nrf2 in astroglia in
the presence of microglia
Immunohistochemistry showed that LPS induced Nrf2
translocation into the nuclei of astroglial cells in the
presence of microglia (Fig. 3e) but not after microglia
depletion (Fig. 3f ).
Inhibition of MAPK eliminated microglial NO production
and astroglial PPP activation, indicating that MAPK
involvement in LPS-induced PPP activation in astroglia is
mediated by microglial NO production
As shown in Fig. 4, NO production presumably by
microglia in response to LPS was eliminated by U0126, a
selective inhibitor of MEK1/2 (Fig. 4b), whereas ROS
production induced by LPS was not affected (Fig. 4a).
Basal production of ROS, but not NO was reduced by
U0126 (Fig. 4a). Similarly, U0126 eliminated NO
production by LPS in microglia (Fig. 4d), while ROS
production was not affected by U0126 (Fig. 4c). We ex-
amined if U0126 treatment affects basal production of
ROS or NO in astroglia or microglia. Neither ROS nor
NO production in astroglia was affected by U0126, while
microglial ROS, but not NO was reduced (Fig. 4e, f ).
NO directly induced Nrf2 activation, leading to PPP
activation in astroglia
Next, we examined whether NO directly induces the ac-
tivation of Keap1/Nrf2 system. HO-1 is a representative
gene whose transcription is governed by Nrf2. Sulfo-
raphane, a potent Nrf2 activator, was used as a positive
control. As shown in Fig. 5a, both sulforaphane and
SNAP, an NO donor, induced significant increases in
HO-1 gene expression in microglia-free astroglia as
assessed by qRT-PCR. Importantly, U0126 did not affect
HO-1 gene expression by sulforaphane or SNAP, indicat-
ing direct action on Nrf2 activation independent of
MAPK. Moreover, NO donor induced PPP activation in
astroglia devoid of microglia (Fig. 5b), and these NO-
induced PPP activation was not affected by U0126
(Fig. 5b). As shown above, PPP activation in astroglial–
microglial culture by LPS was also dependent on the
presence of microglia (Fig. 3c, d). We accordingly inves-
tigated whether microglia-derived NO or ROS or both
induced the activation of astroglial PPP flux. On addition
of U0126, which eliminated NO production from micro-
glia (Fig. 4d), the PPP activation in astroglia also disap-
peared (Fig. 5c), indicating that NO but not ROS is
involved in this microglia–astroglia axis.
Depletion of GSH synthesis induced ROS production in
astroglia devoid of microglia in response to LPS
As shown in Fig. 1d, astroglia express TLR4. Thus,
TLR4-mediated ROS/NO production should be induced
in astroglia in response to LPS. We speculated that high
astroglial ability to erase ROS masked ROS production.
When we inhibited GSH synthesis in astroglia by adding
BSO, an inhibitor of GSH synthesis (Fig. 6a), LPS did in-
duce ROS production (Fig. 6b), but not NO production
(Fig. 6c) in astroglial cell devoid of microglia.
Hypoxia enhanced PPP flux in astroglia in both presence
and absence of microglia
In contrast to LPS stimulation, hypoxia induced in-
creases in PPP flux in both untreated control astroglia
(with microglia; Fig. 7a) and Ara-C/LME-treated
astroglia (without microglia; Fig. 7b), indicating that
hypoxia-induced PPP activation in astroglia is not
dependent on microglia.
(See figure on previous page.)
Fig. 5 Sulforaphane (SL) and NO activate Nrf2 and induce increases in astroglial PPP. Sulforaphane (SL), a well-known activator of Nrf2, increased
HO-1 expression and SNAP, an NO donor, also induced HO-1 expression in the presence of U0126 (a HO-1). mRNA expression of HO-1 in
microglia-free astroglia was analyzed by quantitative real-time polymerase chain reaction. HO-1 fold change was calculated relative to each
control (means ± SD, n = 4). ***P < 0.001 versus each control (grouped t test). SNAP induced increases in PPP flux in microglia-depleted astroglia
and this NO-induced increases in PPP flux was not eliminated by 12-h pretreatment by U0126 (10 μmol/L), indicating a direct action of NO
(b PPP). However, LPS-induced increases in PPP flux in untreated astroglia were eliminated by 12-h pretreatment by U0126 (10 μmol/L) (c PPP).
Values are the means ± SD of four flasks. n.s., not significant, *P < 0.05, **P < 0.01 versus control (grouped t test)
Iizumi et al. Journal of Neuroinflammation  (2016) 13:99 Page 11 of 20
Hypoxia-induced PPP activation in astroglia was not
associated with NO production
Hypoxia-induced PPP activation appeared microglia-
independent, given that hypoxia enhanced PPP flux in
microglia-depleted astroglia. Hypoxia also did not
induce NO production in astroglial cells devoid of
microglia (Fig. 7d). NO production by microglia-
containing astroglia was not enhanced under hypoxia
(Fig. 7c, d), indicating that PPP activation under




Fig. 6 Inhibition of glutathione synthesis uncovers astroglial ROS production. L-buthionine-sulfoximine (BSO; 50 μmol/L for 12 h), an inhibitor of
GSH synthesis reduced astroglial GSH content (a GSH). Values are the means ± SD of four wells. ***P < 0.001 versus control (grouped t test).
Inhibition of glutathione synthesis in astroglia revealed LPS-induced ROS production in astroglia devoid of microglia. The rate of ROS production
in the treated astroglial culture exposed to LPS (0.01 μg/mL) for 12 h (b ROS), and the rate of NO production in the astroglial culture exposed to
LPS (0.01 μg/mL) for 12 h (c NO) in the presence or absence of BSO. BSO pretreatment (50 μmol/L) had been performed for 12 h prior to exposure
to LPS. Values are the means ± SD of six wells. n.s., not significant, *P < 0.05 versus control (grouped t test)
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PPP is activated in association with activated glycolysis
in response to hypoxia.
Hypoxia and TLR4 activation by LPS increased astroglial
PPP flux in an additive manner
To investigate whether LPS-induced PPP increase is
preserved in hypoxic conditions, we assessed the effect
of combined hypoxia and LPS on PPP flux. As shown
in Fig. 8, hypoxia and LPS enhanced PPP flux in an
additive manner, confirming that the two pathways are
independent.
Activation of PPP by sulforaphane, an activator of Nrf2,
eliminated LPS-induced ROS and NO production in
astroglia containing microglia
LPS activates TLR4 in microglia and induces inflamma-
tory responses. In particular, ROS and NO produced by
microglia lead to neuronal damage during ischemic
stroke. As we have shown, NO derived from microglia
enhances PPP activity in astroglia, which may play a role
in reducing ROS and NO, thereby protecting neurons.
To confirm astroglial protective roles, we measured ROS
and NO production in astroglia with microglia after the
activation of astroglial PPP. Sulforaphane, a potent acti-
vator of Nrf2, activated astroglial PPP and basal ROS
production in astroglia [45]. In the present study, we
confirmed that sulforaphane induced HO-1 gene expres-
sion in astroglia (Fig. 5a). Furthermore, sulforaphane
did, indeed, induce increases in glutathione content in
astroglia devoid of microglia (Fig. 9a). Consequently, as
shown in Fig. 9b, c, LPS-induced robust increases in
ROS and NO were completely eliminated. Again, the
effects of sulforaphane on PPP activation that was
observed in WT mouse (Fig. 10a) were eliminated in
A B
C D
Fig. 7 The effects of hypoxia. Hypoxia enhanced PPP flux in microglia-containing and microglia-depleted astroglia, but did not alter NO production.
Astroglia containing microglia (a PPP) and lacking in microglia (b PPP) had been exposed to 1 % hypoxia for 12 h prior to PPP measurement. Values
are means ± SD of four flasks. *P < 0.05, ***P < 0.001 versus normoxia control (grouped t test). Astroglia with (open columns) or without (striped
columns) microglia were exposed to 1 % hypoxia and LPS (0.01 μg/mL) prior to NO measurement. Hypoxia did not induce NO production in
microglia-depleted astroglia and did not elicit increases in NO production in microglia-containing astroglia (d NO) as compared with normoxic
control (c NO). Values are mean ± SD of six wells. *P < 0.05, ***P < 0.001 versus control (grouped t test)
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astroglia prepared from Nrf2-KO mouse (Fig. 10b).
However, hypoxia-induced PPP activation (Fig. 10a) was
preserved in astroglia deficient of Nrf2 (Fig. 10b).
Quantification of metabolites in astroglial pentose-
phosphate pathway by capillary-electrophoresis/
electrospray ionization (CE/ESI) MS
The metabolites of PPP were increased by hypoxia (1 %
O2 for 12 h) in astroglia prepared from WT and Nrf2-
KO mouse. These results are in accordance with those
obtained by the [1-14C]/[6-14C]glucose method. Namely,
the difference of the CO2 production from [1-
14C]glucose
and [6-14C]glucose is a good indication of the cellular
PPP flux. Moreover, hypoxia-induced PPP enhancement
was independent of Nrf2 (Additional file 2).
Neurons do not respond to either LPS stimulation or
hypoxia by increasing PPP flux
In contrast to astroglia, neurons did not respond to
LPS (Fig. 11a) or hypoxia (Fig. 11b) by enhancing PPP
flux, indicating that neuronal cells are susceptible to
oxidative stress.
Discussion
Inflammatory responses by neural cells (neurons and
glial cells) as well as blood cells have been implicated in
the underlying mechanisms of ischemic cell damage
[46–53]. TLRs, in particular TLR4, play important roles
in the initiation and progression of inflammatory
response by intrinsic brain cells, given that brain ische-
mia induces neuronal release or the increased produc-
tion of endogenous ligands of TLR4 (damage-associated
molecular patterns such as high-mobility group box 1
and peroxiredoxin) in a relatively early stage of an ische-
mic event, i.e., within 24 h [9, 54, 55]. There is accumu-
lating evidence that not only immune cells in the brain
parenchyma, such as microglia, but also astroglia and
neurons harbor TLR4 [56–58]. It is likely that microglia
respond to these endogenous TLR4 ligands by producing
inflammatory cytokines and ROS/NO, leading to further
neuronal damage [59]. However, the full role of TLR4 in
non-immune cells has not been elucidated. In the
present study, we confirmed the presence of TLR4 in
astroglia by Western blotting using an astroglial culture
devoid of microglia. However, the role of astroglial TLR4
per se does not appear relevant.
The roles of astroglia in ischemic stroke are disputed.
Astroglial TLR4 may play either a detrimental or benefi-
cial role or both [60]. Gorina et al. reported that TLR4
stimulation by LPS even at a low concentration (0.01 μg/
mL) induced the release of inflammatory cytokines from
astroglia, suggestive of a harmful role [13]. For identifying
the role of TLR4 in astroglia, cultured cells are useful tools
[61–64]. However, usually microglial cells are also present
Fig. 8 The enhancement of PPP flux by LPS and hypoxia. LPS and hypoxia enhanced PPP flux in astroglia in an additive manner. Microglia-containing
astroglia were exposed to LPS (0.01 μg/mL) for 12 h (open columns) or LPS and hypoxia for 12 h (dotted columns). Values are means ± SD of four flasks.
*P < 0.05 compared with LPS(−) controls (grouped t test). #P < 0.05 compared with normoxia controls (grouped t test)
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and may affect the results obtained from astroglial cul-
tures [65–68]. In the present study, we obtained a pure
astroglial culture using Ara-C/LME-treatment. Although
we did not detect cytokine release using this culture,
ROS/NO production was not altered by the addition of
LPS to the pure astroglial culture, whereas it showed dras-
tic increases in the microglia-containing astroglial culture.
In contrast, Bolaños et al. reported the astroglial acti-
vation of PPP flux as a cytoprotective response induced
by LPS (1 μg/mL) through NO [16]. PPP is a cytopro-
tective metabolic pathway of glucose, given that PPP
activation induces NADPH production, which is neces-
sary to recycle the oxidized from of GSH back to the re-
duced form, leading to removal of ROS by GSH
peroxidase [69–71]. Importantly, in ischemic stroke,
ischemia–reperfusion enhances ROS production in the
mitochondria of neurons, leading to further neuronal
damage [72, 73]. Thus, PPP activation after ischemia–
reperfusion could be an important player in preventing
cellular damage during ischemic stroke. Furthermore,
they found that NO has a key role in activating PPP in
astroglia in response to LPS stimulation [16]. The
present study partly supported these beneficial effects of
LPS on astroglia. We identified two important findings
using two different cultures of astroglia with or without
microglia. First, the origin of NO and ROS production in
response to LPS stimulation was coexisting microglia.
NO elimination by MAPK inhibition eliminated increases
in PPP in astroglia, supporting the PPP-activating role of
NO. Second, this NO-induced astroglial PPP activation
was induced via the Keap1/Nrf2 system in astroglia.
Interestingly, MAPK does not seem to be involved in the
basal production of NO in microglia. In contrast, basal
production of ROS in microglia decreased by MAPK
inhibition, indicating different roles of MAPK in micro-
glial production of NO and ROS.
Hypoxia per se induced PPP activation in astroglia by
a completely different mechanism. Hypoxia could poten-
tially activate PPP flux, given that the PPP is a branch
pathway of glycolysis that is well known to be activated
under hypoxic conditions [74, 75]. However, the effects
of hypoxia on PPP flux of astroglial cells have been
extensively examined [75, 76]. Instead, inflammatory
cells such as macrophages alter their metabolic character
to increase glycolysis in response to inflammation, which
is associated with hypoxic environments. With respect
to neurons, oxidative metabolism of glucose is required
to produce sufficient ATP to maintain neuronal action
potentials [77, 78]. In contrast, astroglia energy metabol-
ism is more dependent on glycolysis [78–80]. We have
reported that astroglial glycolysis and its branch path-
way, the PPP, are important for protection of neurons
against oxygen stress [45]. In the present study, we
found that hypoxia-induced activation of the PPP in
astroglia is mediated by a different pathway from that
mediating NO-induced activation of the PPP and that
these two pathways act in an additive manner.
Astroglial cultures always contain a small but appre-
ciable number of microglia [81–83]. The present study
showed that a normal astroglial culture contains as




Fig. 9 The effects of sulforaphane (SL). SL, a potent activator of Nrf2,
increased GSH content (a GSH) and eliminated LPS-induced increases
in ROS and NO. The rate of ROS production (b ROS) and NO
production (c NO) in untreated microglia-containing astroglia that
had been pretreated with DMSO (open columns) or sulforaphane
(10 μmol/L, hatched columns). Values are means ± SD of six wells.
***P < 0.001 versus controls (grouped t test)
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microglia from astroglia is important for distinguishing
the astroglial response to TLR4 stimulation. Ara-C com-
bined with LME eliminates microglia effectively [24, 25].
The mechanism by which LME destroys microglia has
not been fully established. The lysosomal enzyme, which
is abundant in microglia, is involved [29, 30]. In the
present study, we confirmed that this treatment suc-
ceeded in completely eliminating microglia and that
LPS-induced but not hypoxia-induced PPP activation
occurred only in the presence of microglia. Interestingly,
however, TLR4 expression in pure astroglia devoid of
microglia was unaltered, indicating that astroglia per se
express TLR4. Thus, LPS stimulation could possibly
induce astroglial response through TLR4 activation,
whether pro- or anti-inflammatory. We speculated that
astroglial PPP activity is high enough to mask ROS
production in response to LPS. In fact, LPS did induce
increases in ROS production in astroglia in the absence
of microglia after GSH depletion. We do not know why
LPS did not induce NO production in astroglia.
PPP is a cytoprotective metabolic pathway of glucose,
given that PPP activation induces the NADPH produc-
tion that is necessary to recycle the oxidized form of
GSH back to the reduced form, leading to the removal
of ROS by GSH peroxidase [84]. The rate-limiting
enzyme of PPP, G6PDH, is transcriptionally regulated:
the transcriptional factor Nrf2 binds to the ARE located
upstream of the G6PDH gene [18, 85]. Nrf2 is released
from its adaptor protein Keap1 under stress imposed by
ROS and RNS [19]. Thus, ROS or NO can elicit Nrf2
activation, leading to PPP activation. Bolaños et al. indi-
cated that NO induces astroglial PPP activation via
mitochondrial inhibition and resulting activation of
AMP-activated protein kinase (AMPK) [16]. The results
of the present study supported it, since the TCA flux as
assessed by [6-14C]glucose oxidation decreased by NO.
However, increases in PPP flux did not seem to be ex-
plained merely by a decreased flux to the TCA cycle. In
the present study, we confirmed that NO per se induced
Nrf2 activation and increases in PPP flux, and after the
inhibition of NO production from microglia by U0126,
LPS failed to induce PPP activation, even though ROS
production was maintained. NO reportedly activates the
Keap1/Nrf2 system by S-nitrosylation of the Keap1 pro-
tein, facilitating the release of Nrf2 [21]. ROS may also
act as an activator of the Keap1/Nrf2 system through
the modification of thiol residues of Keap1 [86–89]. The
present study, however, did not support a major role of
ROS in activating the Keap1/Nrf2 system.
Another possibility is astroglial TLR4-mediated re-
sponse via MAPK-associated phosphorylation of Nrf2.
The mechanisms by which Nrf2 is activated are mul-
tiple and the phosphorylation of Nrf2 at serine 40 is
one of them [90–93]. Various kinases may phosphoryl-
ate Nrf2 [20]. However, our results showed that
nuclear translocation of Nrf2 was induced only when
microglia were also present. Thus, the direct involve-
ment of MAPK-induced phosphorylation of Nrf2 in
astroglia is unlikely.
TLR4 activation is an important mechanism in ische-
mic stroke, given that ischemia-induced neuronal dam-
age triggers the release of endogenous ligands for TLR4
[9, 53, 94–96]. In the present study, we also examined
the effects of hypoxia per se, given that hypoxia induces
Fig. 10 Sulforaphane (SL)- and hypoxia-induced PPP activation in mouse astroglia. Sulforaphane (SL; 10 μM/L) and hypoxia (1 % O2 for 12 h)
enhanced PPP flux in astroglia prepared from WT (a WT) and Nrf2-deficient mouse (b Nrf2-KO). Values are the means ± SD of four flasks. n.s.,
not significant, *P < 0.05, **P < 0.01 versus control (grouped t test)
Iizumi et al. Journal of Neuroinflammation  (2016) 13:99 Page 16 of 20
AB
Fig. 11 The effects of LPS or hypoxia on PPP flux in neurons. Neither LPS nor hypoxia induce the enhancement of PPP flux in neurons. Neurons
were treated with Ara-C when prepared, but not with LME. Both LPS (0.01 μg/mL) (a PPP) and hypoxia (1 % O2) (b PPP) decreased PPP flux in neurons.
Values are means ± SD of four flasks. **P < 0.01 versus normoxia (grouped t test). Values are mean ± SD of four flasks. *P < 0.05, **P < 0.01, ***P < 0.001
versus controls (grouped t test)
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marked glycolysis. If glycolysis is activated, PPP, a branch
pathway of glycolysis, is simultaneously activated. In
fact, PPP in astroglia was activated irrespective of the
presence of microglia. LPS and hypoxia showed addi-
tive effects on PPP activation in astroglia containing
microglia, indicating that hypoxia and TLR4 activation
act independently. Hypoxia induced the activation of
both glycolysis and PPP. Similarly, LPS induced PPP
activation as well as glycolysis. In a recent study, hyp-
oxia induced PPP activation coupled with glycolytic
activation [97]. In this context, PPP activation is
merely a consequence of glycolytic activation induced
by hypoxia. Whether or not LPS-induced activation of
glycolysis is dependent on the Nrf2 system is unclear
from the results of the present study. These pathways
are probably independent, given that LPS-induced
increases in PPP flux were preserved under hypoxia.
However, in brain ischemia, primary hypoxia causes
cellular damage, and endogenous TLR4 ligands are
released from the damaged cells. It is reasonable to
speculate that hypoxia and TLR4 activation work
independently to protect the living body against oxy-
gen stress, given that ROS exerts deleterious effects
in the progression of neuronal damage, especially
when reperfusion of the occluded artery occurs. The
protective mechanism of astroglia may play important
roles, and its enhancement may lead to a novel thera-
peutic strategy for acute ischemic stroke.
Finally, we treated astroglia with sulforaphane to in-
duce Nrf2 activation as evidenced by HO-1 expression.
By the pretreatment of astroglia with sulforaphane,
which had been confirmed to activate the PPP, ROS and
NO production were completely blocked. Thus, the
activation of PPP by the enhancement of Nrf2 in astro-
glia may lead to a novel therapeutic strategy for stroke.
Conclusions
Astroglia in concert with microglia may play a cytopro-
tective role to counter oxidative stress in stroke via the
activation of PPP. The present study supported the role
of NO, which seemed to be derived from microglia upon
TLR4 stimulation, in increasing flux in astroglial PPP.
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